Answers are grounded in this paper and cite their sources.
Lung cancer remains a leading global cause of cancer-related mortality. As a cornerstone chemotherapeutic for lung cancer, cisplatin is limited by acquired resistance and dose-limiting nephrotoxicity. Multifunctional adjuvants capable of suppressing tumor progression, potentiating cisplatin and alleviating its toxicity are urgently needed for lung cancer therapy. Bardoxolone methyl (CDDOMe), an oleanolic acid-derived triterpenoid, mitigates cisplatin-induced nephrotoxicity and exerts potent anti-lung cancer activity, but the mechanisms underlying the latter remain incompletely elucidated. This study aimed to investigate the anti-lung cancer activity of CDDOMe and characterize its direct molecular target and underlying regulatory mechanism, with a hypothesis that CDDOMe covalently targets YBX1 to exert synergistic antitumor effects with cisplatin. We also sought to define a novel oncogenic signaling axis for potential therapeutic targeting in lung cancer. Activity-based protein profiling (ABPP) was applied to screen the direct binding target of CDDOMe; multiple chemical biology strategies were adopted to verify the binding interaction between CDDOMe and YBX1. Transcriptomic sequencing was conducted to screen differential genes after CDDOMe intervention and pinpoint PFKFB3 as the downstream target of YBX1. Clinical specimen data were analyzed to assess the correlation of YBX1 and PFKFB3 expression with patient survival prognosis. Cell functional assays and combined drug intervention experiments were implemented to characterize the synergistic antitumor effect. CDDOMe covalently modified Lys170 and occupied the RNA recognition pocket within the YBX1 cold-shock domain (CSD) to suppress the function of YBX1. Meanwhile, the glycolysis activator PFKFB3 was identified as a novel downstream target of YBX1. Mechanistically, CDDOMe targeted YBX1 to disrupt its binding to the PFKFB3 promoter and its stabilization of PFKFB3 mRNA, thereby suppressing metastasis and glycolysis. Clinical data analysis revealed that YBX1 expression positively correlates with PFKFB3 expression in lung cancer tissues and predicts poorer overall survival in patients with lung cancer. Combinatorial treatment demonstrated that CDDOMe potentiates the antitumor activity of cisplatin through YBX1 inhibition. In addition, CDDOMe functioned as a multifunctional adjuvant that concurrently mitigated cisplatin-induced nephrotoxicity. This study repurposes CDDOMe as a first‑in‑class YBX1‑targeted covalent small molecule with dual cisplatin‑sensitizing and nephroprotective activities for combinatorial lung cancer therapy. These findings validate the YBX1‑PFKFB3 axis as a potential therapeutic target, thereby providing a novel strategy to improve therapeutic outcomes in lung cancer patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: